1. WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020 [cited 18.06.2021]. Available from URL: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
2.
T.C.S.B. Covid-19 As Bilgilendirme Platformu 2021 [cited 14.11.2021]. Available from URL: https://covid19asi.saglik.gov.tr/.
3.
European Academy of Teachers in General Practice (Network within WONCA Europe). The European definition of general practice/family medicine. Available from URL: https://www.woncaeurope.org/file/3b13bee8-5891-455e-a4cb-a670d7bfdca2/Definition%20EURACTshort%20version%20revised%202011.pdf.
4.
WHO. Infodemic 2020 [cited 20.06.2021]. Available from URL: https://www.who.int/health-topics/infodemic#tab=tab_1.
5.
American Medical Association. Physician COVID-19 Vaccination Study (Final Report). EISAMR 2021 June [cited 4.01.2022]. Available from URL: https://www.ama-assn.org/system/files/2021-06/physician-vaccination-study-topline-report.pdf.
6.
Eniola K, Sykes J. Four reasons for COVID-19 vaccine hesitancy among health care workers, and ways to counter them. Quick Tips, A Blog from FPM Journal 27 April 2021 [cited 4.01.2022]. Available from URL: https://www.aafp.org/journals/fpm/blogs/inpractice/entry/countering_vaccine_hesitancy.html.
7.
Tagliamento M, Agostinetto E, Bruzzone M, et al. Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2021; 103365.
8.
Monin L, Laing AG, Muńoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol 2021; 22(6): 765–778.
9.
WHO. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac: interim guidance, 24 May 2021. Available from URL: https://apps.who.int/iris/handle/10665/341454.
10.
Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021; 21(2): 181–192.
11.
Geisen UM, Berner DK, Tran F, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 2021; 80: 1306–1311.
12.
Perl SH, Uzan-Yulzari A, Klainer H, et al. SARS-CoV-2 – Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women. JAMA 2021; 325(19): 2013–2014, doi: 10.1001/jama.2021.5782.
13.
CDC. COVID-19 Vaccines While Pregnant or Breastfeeding 2021 [cited 18.06.2021]. Available from URL: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html.
14.
Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med 2021; 385: 1535–1536.
15.
Yin F, Wu Z, Xia X, et al. Unfolding the determinants of COVID-19 vaccine acceptance in China. J Med Internet Res 2021; 23(1): e26089.
16.
Chirumbolo S. Vaccination hesitancy and the “myth” on mRNA-based vaccines in Italy in the COVID-19 era: Does urgency meet major safety criteria? J Med Virol 2021; 93(7): 4049–4053.
17.
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383(27): 2603–2615.
18.
Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med 2021; 385: 875–884.
19.
Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med 2021; 27(2): 205–211.
20.
Tanriover MD, Doanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021; 17; 398(10296): 213–222.
21.
FDA. Emergency use authorization (EUA) of the Pfizer-Biontech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) in individuals 12 years age and older. Silver Spring (MS): Food and Drug Administration; 2019.
22.
Shaw RH, Stuart A, Greenland M, et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet 2021; 397(10289): 2043–2046.
23.
Taquet M, Husain M, Geddes JR, et al. Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine. EClinicalMedicine 2021; 39: 101061.
24.
Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384(22): 2092–2101.
25.
MacNeil JR, Su JR, Broder KR, et al. Updated recommendations from the advisory committee on immunization practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients, United States, April 2021. MMWR 2021; 70(17): 651–656.
26.
Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 2021; 80: 1330–1338.
27.
Yamur H. Aile Hekimlii asistanlarnn COVID-19 pandemisi döneminde influena, pnömokok ve COVID-19 alar hakknda bilgi, tutum ve davranlarnn deerlendirilmesi [dissertation]. Ankara: University of Health Sciences Ankara Health Application and Research Center; 2021.
28.
Di Gennaro F, Murri R, Segala FV, et al. Attitudes towards Anti-SARS-CoV2 vaccination among healthcare workers: Results from a national survey in Italy. Viruses 2021; 13(3): 371.
29.
Civelek B, Yazici O, Ozdemir N, et al. Attitudes of physicians towards COVID-19 vaccines and reasons of vaccine hesitancy in Turkey. Int J Clin 2021: e14399.
30.
Wang J, Jing R, Lai X, et al. Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China. Vaccines 2020; 8(3): 482.
31.
Kaplan AK, Sahin MK, Parildar H, et al. The willingness to accept the COVID-19 vaccine and affecting factors among healthcare professionals: a cross-sectional study in Turkey. Int J Clin 2021; e14226.
32.
Adal T, Koyuncu Y, Türkylmaz AS. Surveys in Covid-19 and Post Covid-19 Days. Ankara: Hacettepe University Institute of Population Studies and the United Nations Population Fund Turkey Country Office, 2021 [cited 14.11.2021] Available from URL: https://turkey.unfpa.org/en/publications/surveys-covid-19-and-post-covid-19-days.